PF 06465469Potent ITK inhibitor; also inhibits BTK CAS# 1407966-77-1 |
- LX-4211
Catalog No.:BCC1714
CAS No.:1018899-04-1
- Dapagliflozin
Catalog No.:BCC2552
CAS No.:461432-26-8
- Canagliflozin
Catalog No.:BCC3696
CAS No.:842133-18-0
- Empagliflozin (BI 10773)
Catalog No.:BCC2472
CAS No.:864070-44-0
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 1407966-77-1 | SDF | Download SDF |
PubChem ID | 71450146 | Appearance | Powder |
Formula | C30H33N7O2 | M.Wt | 523.63 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | Soluble to 5 mM in DMSO with gentle warming | ||
Chemical Name | 3-[4-amino-1-[(3R)-1-prop-2-enoylpiperidin-3-yl]pyrazolo[3,4-d]pyrimidin-3-yl]-N-(3-methyl-4-propan-2-ylphenyl)benzamide | ||
SMILES | CC1=C(C=CC(=C1)NC(=O)C2=CC=CC(=C2)C3=NN(C4=C3C(=NC=N4)N)C5CCCN(C5)C(=O)C=C)C(C)C | ||
Standard InChIKey | CGJVMKJGKFEHTL-HSZRJFAPSA-N | ||
Standard InChI | InChI=1S/C30H33N7O2/c1-5-25(38)36-13-7-10-23(16-36)37-29-26(28(31)32-17-33-29)27(35-37)20-8-6-9-21(15-20)30(39)34-22-11-12-24(18(2)3)19(4)14-22/h5-6,8-9,11-12,14-15,17-18,23H,1,7,10,13,16H2,2-4H3,(H,34,39)(H2,31,32,33)/t23-/m1/s1 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Potent inhibitor of interleukin-2 inducible T cell kinase (ITK) (IC50 = 2 nM). Also exhibits inhibitory activity against Bruton's tyrosine kinase (BTK) (IC50 = 2 nM). Displays nanomolar potencies in a cell-based IP1 assay and human whole blood assay (IC50 values are 31 and 48 nM respectively). |
PF 06465469 Dilution Calculator
PF 06465469 Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 1.9097 mL | 9.5487 mL | 19.0975 mL | 38.1949 mL | 47.7436 mL |
5 mM | 0.3819 mL | 1.9097 mL | 3.8195 mL | 7.639 mL | 9.5487 mL |
10 mM | 0.191 mL | 0.9549 mL | 1.9097 mL | 3.8195 mL | 4.7744 mL |
50 mM | 0.0382 mL | 0.191 mL | 0.3819 mL | 0.7639 mL | 0.9549 mL |
100 mM | 0.0191 mL | 0.0955 mL | 0.191 mL | 0.3819 mL | 0.4774 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Scandine Nb-oxide
Catalog No.:BCN7504
CAS No.:140701-69-5
- 4-Aza-5androstan-1-ene- 3-one-17carboxylic acid
Catalog No.:BCC8693
CAS No.:140700-63-6
- 1-Deoxydihydroceramide-1-sulfonic acid
Catalog No.:BCC4964
CAS No.:1407-03-0
- Levatin
Catalog No.:BCN2531
CAS No.:140670-84-4
- Kadsurenin D
Catalog No.:BCN6603
CAS No.:140669-89-2
- 12-Hydroxyjasmonic acid
Catalog No.:BCN6224
CAS No.:140631-27-2
- 4-Ethylsyringol
Catalog No.:BCN3541
CAS No.:14059-92-8
- Cassipourine
Catalog No.:BCN2154
CAS No.:14051-10-6
- Methyl chanofruticosinate
Catalog No.:BCN6223
CAS No.:14050-92-1
- 1,2-Methylenedioxy-3,10,11-trimethoxynoraporphine
Catalog No.:BCN1573
CAS No.:14050-90-9
- Bacitracin Zinc
Catalog No.:BCC4633
CAS No.:1405-89-6
- Bacitracin
Catalog No.:BCC4632
CAS No.:1405-87-4
- JNK-IN-7
Catalog No.:BCC1672
CAS No.:1408064-71-0
- 1-Hydroxymethyl-beta-carboline glucoside
Catalog No.:BCN7026
CAS No.:1408311-12-5
- ICI 215,001 hydrochloride
Catalog No.:BCC5688
CAS No.:140850-02-8
- Aminopotentidine
Catalog No.:BCC6761
CAS No.:140873-26-3
- 4-Chloro-D-phenylalanine
Catalog No.:BCC2637
CAS No.:14091-08-8
- 6-Hydroxy-5,6-dehydrosugiol
Catalog No.:BCN3127
CAS No.:140923-35-9
- (2R,3S)-Chlorpheg
Catalog No.:BCC6805
CAS No.:140924-23-8
- Benzo-18-crown-6 ether
Catalog No.:BCC8850
CAS No.:14098-24-9
- Benzo-15-crown 5-ether
Catalog No.:BCC8849
CAS No.:14098-44-3
- Nerylacetate
Catalog No.:BCN3802
CAS No.:141-12-8
- Ricinoleic acid
Catalog No.:BCC8248
CAS No.:141-22-0
- 2-Aminoethanol
Catalog No.:BCN1756
CAS No.:141-43-5
Improved disease activity with fosdagrocorat (PF-04171327), a partial agonist of the glucocorticoid receptor, in patients with rheumatoid arthritis: a Phase 2 randomized study.[Pubmed:28328159]
Int J Rheum Dis. 2017 Aug;20(8):960-970.
AIM: To assess efficacy and safety of fosdagrocorat (PF-04171327), a potential dissociated agonist of the glucocorticoid receptor, in rheumatoid arthritis (RA) patients. METHODS: This multicenter, double-blind, parallel-group, active- and placebo-controlled Phase 2 study (NCT00938587) randomized 86 patients (1 : 1 : 1 : 1) to receive fosdagrocorat 10 mg, fosdagrocorat 25 mg, prednisone 5 mg or placebo, all with stable background methotrexate therapy. The primary outcome was change from baseline in Disease Activity Score of 28 joints (DAS28-4[C-reactive protein (CRP)]) after 2 weeks of treatment. Secondary outcomes included American College of Rheumatology (ACR) response rates, change from baseline in ACR core components and Health Assessment Questionnaire Disability Index. RESULTS: At week 2, improvements from baseline in DAS28-4(CRP) with fosdagrocorat 10 and 25 mg, prednisone 5 mg and placebo were -1.69, -2.22, -1.17 and -0.96, respectively, and were statistically significantly greater for both fosdagrocorat doses versus placebo (P < 0.05) and for fosdagrocorat 25 mg versus prednisone 5 mg (P < 0.001). The effects of fosdagrocorat on secondary outcomes were generally consistent with those observed for the primary outcome. Adverse events (AEs) were reported for eight (38%), three (14%), four (19%) and 12 (55%) patients treated with fosdagrocorat 10 and 25 mg, prednisone 5 mg and placebo, respectively. Most AEs were mild in severity. Four patients discontinued treatment due to AEs (fosdagrocorat 10 mg, n = 2; placebo, n = 2). There were no serious AEs. CONCLUSION: Fosdagrocorat 10 and 25 mg demonstrated efficacy in improving signs and symptoms in RA patients, with manageable AEs. Additional studies are needed to assess the longer-term safety and efficacy of fosdagrocorat.
Clinical Activity of the gamma-Secretase Inhibitor PF-03084014 in Adults With Desmoid Tumors (Aggressive Fibromatosis).[Pubmed:28350521]
J Clin Oncol. 2017 May 10;35(14):1561-1569.
Purpose Desmoid tumors (aggressive fibromatosis) arise from connective tissue cells or fibroblasts. In general, they are slow growing and do not metastasize; however, locally aggressive desmoid tumors can cause severe morbidity and loss of function. Disease recurrence after surgery and/or radiation and diagnosis of multifocal desmoid tumors highlight the need to develop effective systemic treatments for this disease. In this study, we evaluate objective response rate after therapy with the gamma-secretase inhibitor PF-03084014 in patients with recurrent, refractory, progressive desmoid tumors. Patients and Methods Seventeen patients with desmoid tumors received PF-03084014 150 mg orally twice a day in 3-week cycles. Response to treatment was evaluated at cycle 1 and every six cycles, that is, 18 weeks, by RECIST (Response Evaluation Criteria in Solid Tumors) version 1.1. Patient-reported outcomes were measured at baseline and at every restaging visit by using the MD Anderson Symptoms Inventory. Archival tumor and blood samples were genotyped for somatic and germline mutations in APC and CTNNB1. Results Of 17 patients accrued to the study, 15 had mutations in APC or CTNNB1 genes. Sixteen patients (94%) were evaluable for response; five (29%) experienced a confirmed partial response and have been on study for more than 2 years. Another five patients with prolonged stable disease as their best response remain on study. Patient-reported outcomes confirmed clinician reporting that the investigational agent was well tolerated and, in subgroup analyses, participants who demonstrated partial response also experienced clinically meaningful and statistically significant improvements in symptom burden. Conclusion PF-03084014 was well tolerated and demonstrated promising clinical benefit in patients with refractory, progressive desmoid tumors who receive long-term treatment.
Multireference configuration interaction study of the 27 low-lying states of the PF(+) cation.[Pubmed:28365453]
Spectrochim Acta A Mol Biomol Spectrosc. 2017 Jun 15;181:226-238.
This paper studied the spectroscopic parameters and vibrational properties of 27 Lambda-S and 60Omega states of PF(+) cation. The 27 Lambda-S states were the X(2)Pi, A(2)Sigma(+), B(2)Pi, C(2)Sigma(-), D(2)Delta, a(4)Sigma(-), b(4)Pi, c(4)Sigma(+), d(4)Delta, 2(2)Sigma(+), 3(2)Sigma(+), 4(2)Sigma(+), 2(2)Sigma(-), 3(2)Sigma(-), 3(2)Pi, 4(2)Pi, 5(2)Pi, 6(2)Pi, 2(2)Delta, 3(2)Delta, 1(2)Phi, 2(4)Sigma(-), 3(4)Sigma(-), 2(4)Pi, 3(4)Pi, 1(6)Sigma(-), and 1(6)Pi, which were generated from the first four dissociation limits. The 60Omega states were produced from the 27 Lambda-S states. All the potential energy curves were calculated with the CASSCF method, which was followed by the icMRCI+Q approach. The a(4)Sigma(-), b(4)Pi, and D(2)Delta states were inverted with the spin-orbit coupling effect accounted for. The 2(4)Pi, 2(4)Sigma(-), 2(2)Delta, 3(2)Delta, 3(2)Sigma(+), 4(2)Sigma(+), 1(2)Phi, and 2(2)Sigma(-) states were repulsive whether the spin-orbit coupling effect was included or not, but the 5(2)Pi and D(2)Delta states became repulsive only with the spin-orbit coupling effect included. The C(2)Sigma(-) state was very weakly bound. The a(4)Sigma(-) state had one barrier. The avoided crossings existed between the a(4)Sigma(-) and 2(4)Sigma(-) states, the 2(2)Sigma(+) and 3(2)Sigma(+) states as well as the D(2)Delta and 2(2)Delta states. Core-valence correlation and scalar relativistic corrections were taken into account. The extrapolation to the complete basis set limit was done. The spectroscopic parameters and vibrational properties were determined. The transition dipole moments were calculated and the Franck-Condon factors of some electric dipole transitions were evaluated. The spin-orbit coupling effect on the spectroscopic and vibrational properties was discussed.
Entrapment of DyP-type peroxidase from Pseudomonas fluorescens Pf-5 into Ca-alginate magnetic beads.[Pubmed:28326617]
Biotechnol Appl Biochem. 2018 Mar;65(2):238-245.
The aim of this study was to investigate the optimal conditions for the immobilization and stabilization of DyP1B dye decolorizing peroxidases type B (DyP1B) from Pseudomonas fluorescens Pf-5 immobilized in Ca-alginate ferromagnetic beads. The immobilized DyP1B was used in the degradation of the Reactive Blue 5 (RB5) synthetic dye. The enzyme was successfully entrapped in a Ca-alginate matrix and showed an encapsulation efficiency of 94%. The concentration of DyP1B (0.8 mg mL(-1) ), 2% of alginate and magnetite (10.0 mg mL(-1) ) was optimal for immobilization. The immobilized DyP1B showed optimum activity at pH 7.0 and 40 degrees C compared with pH 5.5 and 30 degrees C for free peroxidase. Reusability studies showed that after five cycles, the immobilized DyP1B system retained more than 58% of its initial activity. The immobilized DyP1B was able to decolorize RB5 at concentrations of 0.1, 0.05, and 0.01% (w v(-1) ) with efficiency rates of about 20, 29, and 45%, respectively. The immobilization of DyP1B in alginate beads with the addition of Fe3 O4 increased its catalytic and applicative potential.
Covalent inhibitors of interleukin-2 inducible T cell kinase (itk) with nanomolar potency in a whole-blood assay.[Pubmed:23098091]
J Med Chem. 2012 Nov 26;55(22):10047-63.
We wish to report a strategy that targets interleukin-2 inducible T cell kinase (Itk) with covalent inhibitors. Thus far, covalent inhibition of Itk has not been disclosed in the literature. Structure-based drug design was utilized to achieve low nanomolar potency of the disclosed series even at high ATP concentrations. Kinetic measurements confirmed an irreversible binding mode with off-rate half-lives exceeding 24 h and moderate on-rates. The analogues are highly potent in a cellular IP1 assay as well as in a human whole-blood (hWB) assay. Despite a half-life of approximately 2 h in resting primary T cells, the covalent inhibition of Itk resulted in functional silencing of the TCR pathway for more than 24 h. This prolonged effect indicates that covalent inhibition is a viable strategy to target the inactivation of Itk.